<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012051</url>
  </required_header>
  <id_info>
    <org_study_id>CKTO-2000-06</org_study_id>
    <secondary_id>CDR0000068476</secondary_id>
    <secondary_id>HOVON-44</secondary_id>
    <secondary_id>HOVON-44/CKVO-2000-06</secondary_id>
    <secondary_id>EU-20042</secondary_id>
    <secondary_id>ISRCTN95614846</secondary_id>
    <nct_id>NCT00012051</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Commissie Voor Klinisch Toegepast Onderzoek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Peripheral stem cell&#xD;
      transplant may be able to replace immune cells that were destroyed by the chemotherapy.&#xD;
      Monoclonal antibodies, such as rituximab, can block tumor growth in different ways. Some&#xD;
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill&#xD;
      them or carry tumor-killing substances to them. It is not yet known if giving more than one&#xD;
      drug (combination chemotherapy) plus peripheral stem cell transplant is more effective with&#xD;
      or without monoclonal antibody therapy in treating non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well chemotherapy plus peripheral&#xD;
      stem cell transplant with or without monoclonal antibody therapy works in treating patients&#xD;
      with relapsed non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the partial and complete response rates in patients with relapsed, CD20&#xD;
           positive, aggressive B-cell non-Hodgkin's lymphoma treated with dexamethasone,&#xD;
           cisplatin, and cytarabine in combination with etoposide, ifosfamide, and methotrexate&#xD;
           with or without rituximab followed by carmustine, etoposide, cytarabine, melphalan, and&#xD;
           autologous peripheral blood stem cell transplantation (APBSCT).&#xD;
&#xD;
        -  Compare the effect of APBSCT with or without rituximab on the overall and event-free&#xD;
           survival of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center. Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive DHAP induction chemotherapy comprising dexamethasone orally or&#xD;
           IV on days 1-4, cisplatin IV continuously over 24 hours on day 1, and cytarabine IV over&#xD;
           3 hours every 12 hours on day 2. Beginning 3-4 weeks after DHAP, patients receive VIM&#xD;
           induction chemotherapy comprising etoposide IV over 2 hours on days 1, 3, and 5;&#xD;
           ifosfamide IV over 1 hour on days 1-5; and methotrexate IV on days 1 and 5. Beginning&#xD;
           3-4 weeks after VIM, patients with partial or complete response after DHAP and VIM&#xD;
           receive a second course of DHAP (patients with progressive or unresponsive disease after&#xD;
           DHAP but responsive disease after VIM receive a second course of VIM) followed by&#xD;
           filgrastim (G-CSF) subcutaneously beginning on day 10 and continuing until a target&#xD;
           number of cells are collected.&#xD;
&#xD;
        -  Arm II: Patients receive induction chemotherapy and G-CSF as in arm I. At 1 day after&#xD;
           the last dose of each chemotherapy course, patients also receive rituximab IV once for a&#xD;
           maximum of 3 courses.&#xD;
&#xD;
      At 4-5 weeks after the completion of the last induction chemotherapy course, responsive&#xD;
      patients in both arms receive BEAM conditioning chemotherapy comprising carmustine IV over 60&#xD;
      minutes on day -6, etoposide IV over 60 minutes and cytarabine IV over 30 minutes on days -5&#xD;
      to -2, and melphalan IV over 15 minutes on day -1. Patients undergo autologous peripheral&#xD;
      blood stem cell transplantation on day 0. After transplantation, patients in partial&#xD;
      remission may undergo radiotherapy to nodal sites with residual tumor mass.&#xD;
&#xD;
      Patients are followed every 6 months for 3 years and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 296-340 patients (148-170 per treatment arm) will be accrued&#xD;
      for this study within 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed relapsed B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Diffuse large cell B-cell lymphoma&#xD;
&#xD;
               -  Grade III follicular center-cell lymphoma&#xD;
&#xD;
               -  Primary mediastinal B-cell lymphoma&#xD;
&#xD;
          -  CD20 positive&#xD;
&#xD;
          -  First relapse after doxorubicin containing regimen&#xD;
&#xD;
          -  Documented remission of at least 3 months after first-line chemotherapy&#xD;
&#xD;
          -  No Epstein-Barr virus post-transplantation lymphoproliferative disorder&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No hepatic dysfunction&#xD;
&#xD;
          -  Bilirubin less than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases less than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No renal dysfunction&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 40 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe cardiac dysfunction&#xD;
&#xD;
          -  No New York Heart association class II-IV heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe pulmonary dysfunction&#xD;
&#xD;
          -  Vital capacity or diffusion capacity at least 70% predicted unless related to NHL&#xD;
             involvement&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No intolerance to exogenous protein administration&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 1 month since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 month since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edo Vellenga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis - Locatie Leyenburg</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden - Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken - locatie Sophia</name>
      <address>
        <city>Zwolle</city>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008 Jan 15;111(2):537-43. Epub 2007 Oct 30.</citation>
    <PMID>17971487</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

